190 related articles for article (PubMed ID: 37828105)
21. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Liu X; Yao J; Song L; Zhang S; Huang T; Li Y
J Immunother Cancer; 2019 Aug; 7(1):204. PubMed ID: 31383016
[TBL] [Abstract][Full Text] [Related]
22. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
23. Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: Bioinformatics analysis and experimental validation.
Li L; Cheng H; Gong L; Huang Y; Yang J; Yan Q; Dai S; Wang J
Gene; 2024 Apr; 902():148156. PubMed ID: 38211899
[TBL] [Abstract][Full Text] [Related]
24. A2M is a potential core gene in intrahepatic cholangiocarcinoma.
Zhang G; Liu X; Sun Z; Feng X; Wang H; Hao J; Zhang X
BMC Cancer; 2022 Jan; 22(1):5. PubMed ID: 34979994
[TBL] [Abstract][Full Text] [Related]
25. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
[TBL] [Abstract][Full Text] [Related]
26. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
Yu WL; Yu G; Dong H; Chen K; Xie J; Yu H; Ji Y; Yang GS; Li AJ; Cong WM; Jin GZ
J Gastroenterol; 2020 Dec; 55(12):1171-1182. PubMed ID: 33089343
[TBL] [Abstract][Full Text] [Related]
27. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
28. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma.
Tamai K; Nakamura M; Mizuma M; Mochizuki M; Yokoyama M; Endo H; Yamaguchi K; Nakagawa T; Shiina M; Unno M; Muramoto K; Sato I; Satoh K; Sugamura K; Tanaka N
Cancer Sci; 2014 Jun; 105(6):667-74. PubMed ID: 24673799
[TBL] [Abstract][Full Text] [Related]
29. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
[TBL] [Abstract][Full Text] [Related]
30. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
Xian F; Ren D; Bie J; Xu G
Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
[TBL] [Abstract][Full Text] [Related]
32. circHMGCS1-016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma.
Xu YP; Dong ZN; Wang SW; Zheng YM; Zhang C; Zhou YQ; Zhao YJ; Zhao Y; Wang F; Peng R; Tang MC; Bai DS; Huang XY; Guo CY
J Exp Clin Cancer Res; 2021 Sep; 40(1):290. PubMed ID: 34526098
[TBL] [Abstract][Full Text] [Related]
33. Dissecting Intra-Tumoral Changes Following Immune Checkpoint Blockades in Intrahepatic Cholangiocarcinoma
Sun BY; Zhou C; Guan RY; Liu G; Yang ZF; Wang ZT; Gan W; Zhou J; Fan J; Yi Y; Qiu SJ
Front Immunol; 2022; 13():871769. PubMed ID: 35558087
[TBL] [Abstract][Full Text] [Related]
34. Machine learning-based solution reveals cuproptosis features in inflammatory bowel disease.
Liu L; Liang L; Yang C; Chen Y
Front Immunol; 2023; 14():1136991. PubMed ID: 37275904
[TBL] [Abstract][Full Text] [Related]
35. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
Yugawa K; Itoh S; Yoshizumi T; Morinaga A; Iseda N; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Int J Clin Oncol; 2021 Oct; 26(10):1901-1910. PubMed ID: 34117554
[TBL] [Abstract][Full Text] [Related]
36. Screening a redox library identifies the anti-tumor drug Hinokitiol for treating intrahepatic cholangiocarcinoma.
Bai P; Ge C; Yang H; Chen H; Wan L; Zhang Y; Zhang B; Zeng Q; Fan Z; Pei X; Yue W; Yan X
Front Biosci (Landmark Ed); 2022 Jan; 27(1):18. PubMed ID: 35090323
[TBL] [Abstract][Full Text] [Related]
37. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
38. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
39. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Shi GM; Huang XY; Wu D; Sun HC; Liang F; Ji Y; Chen Y; Yang GH; Lu JC; Meng XL; Wang XY; Sun L; Ge NL; Huang XW; Qiu SJ; Yang XR; Gao Q; He YF; Xu Y; Sun J; Ren ZG; Fan J; Zhou J
Signal Transduct Target Ther; 2023 Mar; 8(1):106. PubMed ID: 36928584
[TBL] [Abstract][Full Text] [Related]
40. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]